Literature DB >> 20074933

Understanding the problem of inadequately staging early ovarian cancer.

P J Timmers1, A H Zwinderman, C Coens, I Vergote, J B Trimbos.   

Abstract

BACKGROUND: Early ovarian cancer patients are often incompletely staged during initial surgery.(1-3) This omission can have serious adverse consequences for the prognosis of patients as the completeness of surgical staging has been identified as an independent prognostic parameter for survival.(4,5) The reasons for the problem of inadequate staging of early ovarian cancer are largely unknown. We have analysed the data of a large randomised trial in early ovarian cancer in which detailed information of the surgical staging procedure was monitored.(5)
METHODS: Data of the EORTC Adjuvant ChemoTherapy In Ovarian Neoplasm (ACTION) Trial were used in which 448 early ovarian cancer patients were randomised between postoperative chemotherapy in one arm and observation following surgery in the other. In this trial strict criteria for surgical staging were advised but optimal, complete staging was performed in only 1/3 of patients. Staging characteristics of the incompletely staged patients were analysed and factors that could explain the failure to perform a complete staging were studied.
RESULTS: Sampling of para-aortic nodes was omitted in 78% of the incompletely staged patients, while 52% of these patients had no pelvic lymph node dissection. Taking blind biopsies from different peritoneal sites was not performed in more than 1/3 of the incompletely staged group. Omission of the staging steps ranged from 3% (infracolic omentectomy) to 55% (biopsy of the right hemi-diaphragm). A significant difference (p=0.04) between the fraction of completely staged patients was found when comparing institutes who entered less than 5 patients (21%) versus those who included more than 20 patients (37%) in the trial.
CONCLUSIONS: Even in a randomised trial in which comprehensive surgical staging was strongly advised in the study protocol the majority of patients (66%) were incompletely staged. Factors relating to a lack of surgical skills attributed most to the number of incompletely staged patients, but insufficient knowledge of the tumour behaviour and routes of spread of ovarian cancer also contributed substantially to this problem. Multicentre trials recruiting patients from many institutes with small volume contribution to the study, run the risk of inadequate adherence to the study protocol. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20074933     DOI: 10.1016/j.ejca.2009.12.012

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  If the Mountain Does Not Come to Mohammad: The Significance of Guest Operations for Early Stage Ovarian Cancer.

Authors:  Inge T A Peters; Carolien van Haaften; J Baptist Trimbos
Journal:  J Gynecol Surg       Date:  2014-10-01

Review 2.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Brett A Winter-Roach; Henry C Kitchener; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

3.  Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management.

Authors:  Vincenzo Dario Mandato; Martino Abrate; Pierandrea De Iaco; Debora Pirillo; Gino Ciarlini; Maurizio Leoni; Giuseppe Comerci; Alessandro Ventura; Bruno Lenzi; Andrea Amadori; Federica Rosati; Ruby Martinello; Rossana De Palma; Chiara Ventura; Laura Maria Beatrice Belotti; Debora Formisano; Giovanni Battista La Sala
Journal:  J Ovarian Res       Date:  2013-03-31       Impact factor: 4.234

4.  Optimal treatment of early-stage ovarian cancer.

Authors:  F Collinson; W Qian; R Fossati; A Lissoni; C Williams; M Parmar; J Ledermann; N Colombo; A Swart
Journal:  Ann Oncol       Date:  2014-03-14       Impact factor: 32.976

5.  Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.

Authors:  Céline Montavon Sartorius; Uzma Mirza; Andreas Schötzau; Gillian Mackay; Daniel Fink; Neville F Hacker; Viola Heinzelmann-Schwarz
Journal:  Cancer Manag Res       Date:  2018-10-17       Impact factor: 3.989

6.  Early-Stage Ovarian Malignancy Score versus Risk of Malignancy Indices: Accuracy and Clinical Utility for Preoperative Diagnosis of Women with Adnexal Masses.

Authors:  Phichayut Phinyo; Jayanton Patumanond; Panprapha Saenrungmuaeng; Watcharin Chirdchim; Tanyong Pipanmekaporn; Apichat Tantraworasin; Theera Tongsong; Charuwan Tantipalakorn
Journal:  Medicina (Kaunas)       Date:  2020-12-16       Impact factor: 2.430

7.  Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice.

Authors:  P Laven; J J Beltman; J E Bense; M A van der Aa; T Van Gorp; M C Vos; D Boll; Hgj Arts; N Reesink; J B Trimbos; Rfpm Kruitwagen
Journal:  Surg Open Sci       Date:  2021-10-14

Review 8.  Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.

Authors:  Theresa A Lawrie; Brett A Winter-Roach; Pauline Heus; Henry C Kitchener
Journal:  Cochrane Database Syst Rev       Date:  2015-12-17

9.  Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.

Authors:  Celine Montavon; Uzma Mirza; Andre Fedier; Andreas Schoetzau; Rosanna Zanetti Dällenbach; Viola Heinzelmann-Schwarz
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

10.  Ovarian cancer surgery in Germany: An analysis of the nationwide hospital file 2005-2015.

Authors:  Pietro Trocchi; Pawel Mach; Karl Rainer Kimmig; Andreas Stang
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.